Triple-Negative Breast Cancer

Chaudhary, Lubna N.; Wilkinson, Katheryn Hope; Kong, Amanda L.

doi:10.1016/j.soc.2017.08.004

Cited by 114 publications

(54 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NACT has been shown to be as effective as adjuvant chemotherapy in terms of outcomes and is now considered as a possible standard option and a preferred approach for a select subset of BC patients. 16 Multiple studies have shown that a patient's response to NACT is correlated with overall prognosis and disease-free survival. 17 Specifically, patients who have a pathological complete response (pCR) after NACT exhibit better overall diseasefree survival and better long-term outcome than those with residual disease (RD).…”

Section: Clinical Backgroundmentioning

confidence: 99%

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies

Desa

Bhanote

Hill³

et al. 2019

J. Biomed. Opt.

View full text Add to dashboard Cite

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies," J.Abstract. Neoadjuvant chemotherapy (NACT) is routinely administered to subsets of breast cancer patients, including triple negative (TN) or human epidermal growth factor receptor 2-positive (HER2+) cancers. After NACT and subsequent surgical resection, 5% to 30% of patients have no residual invasive carcinoma, termed pathological complete response. Unfortunately, many patients experience little-to-no response after NACT and unnecessarily suffer its side effects. Methods are needed to predict an individual patient's response to NACT. Core needle biopsies, taken before NACT, consist of tumor cells and the surrounding extracellular matrix. We performed second-harmonic generation (SHG) imaging of fibrillar collagen in core needle biopsy sections as a possible predictor of response to NACT. The ratio of forward-to-backward scattering (F/B) SHG was assessed in the "tumor bulk" and "tumor-host interface" in HER2+ and TN core needle biopsy sections. Patient response was classified post-treatment using the Residual Cancer Burden (RCB) score. In HER2+ biopsies, RCB class was associated with F/B derived from the tumor-stromal interface, but not tumor bulk. F/B was not associated with RCB class in TN biopsies. These findings suggest that F/B from needle biopsy sections may be a useful predictor of which patients will respond favorably to NACT, with the potential to help reduce overtreatment. © The Authors.Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.

show abstract

Section: Clinical Backgroundmentioning

confidence: 99%

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies

Desa

Bhanote

Hill³

et al. 2019

J. Biomed. Opt.

View full text Add to dashboard Cite

show abstract

“…Neoadjuvant chemotherapy has become more common for patients with operable disease, especially in patients with TNBC [4,20,21], while it was initially used only for locally advanced or inflammatory breast cancer. TNBC is an aggressive subtype of breast cancer with a heterogeneous response to therapy [4,20]. Since pCR occurs in only 40–60% of TNBC patients who received neoadjuvant chemotherapy, it is urgent to develop effective biomarkers specific for TNBC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Because of the aggressive feature of TNBC than other breast cancer subtypes, TNBC is correlated with early recurrence as well as more frequent distant blood metastasis; therefore, TNBC patients usually have poor overall prognosis. Lehmann and colleagues have identified six subtypes of TNBC with gene expression profiles [3], and they concluded these subtypes might have distinct phenotypes and variable sensitivity to chemotherapy [4].…”

Section: Introductionmentioning

confidence: 99%

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients

2019

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. TNBC is highly aggressive and associated with poor prognosis. The present study aimed to compare gene expression between TNBC patients with pathological complete response (pCR) and those with not complete response (nCR) to neoadjuvant chemotherapy. Microarray data of 16 TNBC patients received neoadjuvant chemotherapy were identified from the Gene Expression Omnibus database and 10 patients of them had pCR. We found that 250 coding genes and 155 long noncoding RNAs (lncRNAs) were statistically differentially expressed between patients with pCR and nCR. Receiver operator characteristic curve and area under the curve (AUC) were calculated to assess predictive value of differentially expressed genes. A gene signature of three coding genes and two lncRNA was developed: 2.318*TCF3 + 7.349*CREB1 + 0.891*CEP44 + 0.091*NR_023392.1 + 1.424*NR_048561.1 − 106.682. The gene signature was further validated and had an AUC = 0.829. In summary, we profiled gene expression in pCR patients and developed a gene signature, which was effective to predict pCR among TNBC patients received neoadjuvant chemotherapy.

show abstract

“…TNBC has a distinct metastatic pattern. It is a highgrade invasive ductal carcinoma (2) and often spreads to the brain and lungs (3). TNBC is characterized by its poor prognosis and aggressive biological behavior.…”

Section: Introductionmentioning

confidence: 99%

“…However, TNBC patients who do not achieve pCR are very likely to suffer from early recurrence and die from metastatic diseases. Immunotherapy for TNBC is still under clinical trials (2,7).…”

Section: Introductionmentioning

confidence: 99%

Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study

Kwan

Gong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) has the worst overall survival among all breast cancer subtypes; 80% of TNBC harbors TP53 mutation. Gambogic acid (GA) is an herbal compound isolated from the dry brownish gamboge resin of Garcinia hanburyi. A new family of biodegradable polymer, the folate (FA)-conjugated arginine-based poly(ester urea urethane)s nanoparticles (FA-Arg-PEUU NP), was developed as nano-carrier for GA. Its anti-TNBC effects and the underlying mechanism of action were examined. The average diameters of FA-Arg-PEUU NP and GA-loaded FA-Arg-PEUU NP (NP-GA) in water are around 165 and 220nm, respectively. Rhodamine-tagged FA-Arg-PEUU NP shows that the conjugation of FA onto Arg-PEUU NPs facilitates the internalization of FA-Arg-PEUU-NP into TNBC. Compared to free-GA at the same GA concentrations, NP-GA exhibits higher cytotoxicity in both TP53-mutated and non-TP53 expressed TNBC cells by increasing intrinsic and extrinsic apoptosis. In HCC1806-bearing xenograft mouse model, the targeted delivery of GA by the FA-Arg-PEUU-NP nano-carriers to the tumor sites results in a more potent anti-TNBC effect and lower toxicity towards normal tissues and organs when compared to free GA. Furthermore, NP-GA also reduces the tumor-associated macrophage (TAM) M1/M2 ratio, suggesting that the use of Arg-based nanoparticles as carriers for GA not only makes the surface of the nanoparticles positively charged, but also confers on to the nanoparticles an ability to modulate TAM polarization. Our data clearly demonstrate that NP-GA exhibits potent anti-TNBC effects with reduced off-target toxicity, which represents novel alternative targeted therapeutics for TNBC treatment.

show abstract

Triple-Negative Breast Cancer

Cited by 114 publications

References 82 publications

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study

Contact Info

Product

Resources

About